The stock's fall snapped a four-day winning streak.

Shares of Incyte Corp. INCY rose 1.39% to $62.78 Monday, on what proved to be an all-around positive trading session for the ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session ...

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...